Crystallopathies

New England Journal of Medicine

Volumn 374, Issue 25, 2016, Pages 2465-2476

  Mulay, Shrikant R ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; AMYLOID; BILE PIGMENT; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CALCIUM PHOSPHATE DIBASIC; CALCIUM PYROPHOSPHATE; CHOLESTEROL; HYDROXYAPATITE; STRUVITE; WEDDELLITE; WHEWELLITE;

ALZHEIMER DISEASE; AMYLOIDOSIS; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BREAST CALCIFICATION; CHOLELITHIASIS; CHOLESTEROL EMBOLISM; CHOLESTEROL ESTER STORAGE DISEASE; CHONDROCALCINOSIS; CLINICAL FEATURE; CLONAL ANERGY; COMMON BILE DUCT STONE; CRYSTAL; CRYSTALLOPATHY; CYTOTOXICITY; GRANULOMA; HEMOCHROMATOSIS; HUMAN; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; NEPHROLITHIASIS; NERVOUS SYSTEM INFLAMMATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBSTRUCTION; OXALOSIS 1; PARTICLE SIZE; PRIORITY JOURNAL; PSEUDOGOUT; REVIEW; SIALOLITHIASIS; STONE FORMATION; TUMOR CALCINOSIS; UROLITHIASIS; CALCINOSIS; CELL DEATH; COMPLICATION; CRYSTALLIZATION; INFLAMMATION;

CALCINOSIS; CELL DEATH; CRYSTALLIZATION; HUMANS; INFLAMMATION;

EID: 84975497175     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1601611     Document Type: Review

References (77)

1. Moitra S, Puri R, Paul D, Huang YC. Global perspectives of emerging occupational and environmental lung diseases. Curr Opin Pulm Med 2015;21:114-20.
2. Kzhyshkowska J, Gudima A, Riabov V, Dollinger C, Lavalle P, Vrana NE. Macrophage responses to implants: prospects for personalized medicine. J Leukoc Biol 2015;98:953-62.
3. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22.
4. Harris BJ, Dalhaimer P. Particle shape effects in vitro and in vivo. Front Biosci (Schol Ed) 2012;4:1344-53.
5. Worcester EM, Coe FL. Calcium kidney stones. N Engl J Med 2010;363:954-63.
6. Asselman M, Verhulst A, De Broe ME, Verkoelen CF. Calcium oxalate crystal adherence to hyaluronan-, osteopontin-, and CD44-expressing injured/regenerating tubular epithelial cells in rat kidneys. J Am Soc Nephrol 2003;14:3155-66.
7. Karaolanis G, Lionaki S, Moris D, Palla VV, Vernadakis S. Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts. Transplant Rev (Orlando) 2014;28:182-7.
8. Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med 2013;369:649-58.
9. Syed F, Mena-Gutierrez A, Ghaffar U. A case of iced-tea nephropathy. N Engl J Med 2015;372:1377-8.
10. Garneau AP, Riopel J, Isenring P. Acute methotrexate-induced crystal nephropathy. N Engl J Med 2015;373:2691-3.
11. Janoudi A, Shamoun FE, Kalavakunta JK, Abela GS. Cholesterol crystal induced arterial inflammation and destabilization of atherosclerotic plaque. Eur Heart J 2015 December 24 (Epub ahead of print).
12. Quinones A, Saric M. The cholesterol emboli syndrome in atherosclerosis. Curr Atheroscler Rep 2013;15:315.
13. Hutcheson JD, Goettsch C, Rogers MA, Aikawa E. Revisiting cardiovascular calcification: a multifaceted disease requiring a multidisciplinary approach. Semin Cell Dev Biol 2015;46:68-77.
14. Linkermann A, Stockwell BR, Krautwald S, Anders HJ. Regulated cell death and inflammation: an auto-amplification loop causes organ failure. Nat Rev Immunol 2014;14:759-67.
15. Huang D, Zhou H, Gao J. Nanoparticles modulate autophagic effect in a dispersitydependent manner. Sci Rep 2015;5:14361.
16. Liu Z, Xiao Y, Chen W, et al. Calcium phosphate nanoparticles primarily induce cell necrosis through lysosomal rupture: the origination of material cytotoxicity. J Mater Chem B 2014;2:3480-9.
17. Mulay SR, Desai J, Kumar SV, et al. Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis. Nat Commun 2016;7:10274.
18. Linkermann A, Green DR. Necroptosis. N Engl J Med 2014;370:455-65.
19. Linkermann A, Skouta R, Himmerkus N, et al. Synchronized renal tubular cell death involves ferroptosis. Proc Natl Acad Sci U S A 2014;111:16836-41.
20. Kearney CJ, Cullen SP, Clancy D, Martin SJ. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis. FEBS J 2014;281:4921-34.
21. Fortes GB, Alves LS, De Oliveira R, et al. Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production. Blood 2012;119:2368-75.
22. Slater AF, Cerami A. Inhibition by chloroquine of a novel haem polymerase enzyme activity in malaria trophozoites. Nature 1992;355:167-9.
23. Desai J, Kumar SV, Mulay SR, et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. Eur J Immunol 2016;46:223-9.
24. Schauer C, Janko C, Munoz LE, et al. Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines. Nat Med 2014;20:511-7.
25. Allam R, Kumar SV, Darisipudi MN, Anders HJ. Extracellular histones in tissue injury and inflammation. J Mol Med (Berl) 2014;92:465-72.
26. Unno H, Futamura K, Morita H, et al. Silica and double-stranded RNA synergistically induce bronchial epithelial apoptosis and airway inflammation. Am J Respir Cell Mol Biol 2014;51:344-53.
27. Rock KL, Latz E, Ontiveros F, Kono H. The sterile inflammatory response. Annu Rev Immunol 2010;28:321-42.
28. Samstad EO, Niyonzima N, Nymo S, et al. Cholesterol crystals induce complementdependent inflammasome activation and cytokine release. J Immunol 2014;192:2837-45.
29. Franklin BS, Mangan MS, Latz E. Crystal formation in inflammation. Annu Rev Immunol 2016;34:173-202.
30. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006;440:237-41.
31. Strowig T, Henao-Mejia J, Elinav E, Flavell R. Inflammasomes in health and disease. Nature 2012;481:278-86.
32. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010;464:1357-61.
33. Mulay SR, Kulkarni OP, Rupanagudi KV, et al. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion. J Clin Invest 2013;123:236-46.
34. Ea HK, So A, Liote F, Busso N. Basic calcium phosphate crystals induce NLRP3 inflammasome activation: the in vitro and in vivo face to face. Proc Natl Acad Sci USA 2011;108(50):E1361-2.
35. Diamantopoulos AP, Brodin C, Hetland H, Haugeberg G. Interleukin 1β blockade improves signs and symptoms of chronic calcium pyrophosphate crystal arthritis resistant to treatment. J Clin Rheumatol 2012;18:310-1.
36. Prencipe G, Caiello I, Cherqui S, et al. Inflammasome activation by cystine crystals: implications for the pathogenesis of cystinosis. J Am Soc Nephrol 2014;25:1163-9.
37. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008;9:847-56.
38. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-7.
39. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008;453:1122-6.
40. Dostert C, Guarda G, Romero JF, et al. Malarial hemozoin is a Nalp3 inflammasome activating danger signal. PLoS One 2009;4(8):e6510.
41. Darisipudi MN, Thomasova D, Mulay SR, et al. Uromodulin triggers IL-1β-dependent innate immunity via the NLRP3 inflammasome. J Am Soc Nephrol 2012;23:1783-9.
42. Baroja-Mazo A, Martin-Sanchez F, Gomez AI, et al. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol 2014;15:738-48.
43. Komada T, Usui F, Kawashima A, et al. Role of NLRP3 inflammasomes for rhabdomyolysis-induced acute kidney injury. Sci Rep 2015;5:10901.
44. Heneka MT, Kummer MP, Stutz A, et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature 2013;493:674-8.
45. Codolo G, Plotegher N, Pozzobon T, et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One 2013;8(1):e55375.
46. Shi F, Yang L, Kouadir M, et al. The NALP3 inflammasome is involved in neurotoxic prion peptide-induced microglial activation. J Neuroinflammation 2012;9:73.
47. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol 2010;11:897-904.
48. Pauwels NS, Bracke KR, Dupont LL, et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011;38:1019-28.
49. Baron L, Gombault A, Fanny M, et al. The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine. Cell Death Dis 2015;6:e1629.
50. Cullen SP, Kearney CJ, Clancy DM, Martin SJ. Diverse activators of the NLRP3 inflammasome promote IL-1β secretion by triggering necrosis. Cell Rep 2015;11:1535-48.
51. Dinarello CA. The role of the interleukin-1.receptor antagonist in blocking inflammation mediated by interleukin-1. N Engl J Med 2000;343:732-4.
52. Kiyotake R, Oh-Hora M, Ishikawa E, Miyamoto T, Ishibashi T, Yamasaki S. Human Mincle binds to cholesterol crystals and triggers innate immune responses. J Biol Chem 2015;290:25322-32.
53. Hari A, Zhang Y, Tu Z, et al. Activation of NLRP3 inflammasome by crystalline structures via cell surface contact. Sci Rep 2014;4:7281.
54. Schorn C, Frey B, Lauber K, et al. Sodium overload and water influx activate the NALP3 inflammasome. J Biol Chem 2011;286:35-41.
55. Gross O, Yazdi AS, Thomas CJ, et al. Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1. Immunity 2012;36:388-400.
56. Halle A, Hornung V, Petzold GC, et al. The NALP3 inflammasome is involved in the innate immune response to amyloidbeta. Nat Immunol 2008;9:857-65.
57. Kalantari P, DeOliveira RB, Chan J, et al. Dual engagement of the NLRP3 and AIM2 inflammasomes by plasmodiumderived hemozoin and DNA during malaria. Cell Rep 2014;6:196-210.
58. Saemann MD, Weichhart T, Zeyda M, et al. Tamm-Horsfall glycoprotein links innate immune cell activation with adaptive immunity via a Toll-like receptor-4-dependent mechanism. J Clin Invest 2005;115:468-75.
59. Liu G, Cheresh P, Kamp DW. Molecular basis of asbestos-induced lung disease. Annu Rev Pathol 2013;8:161-87.
60. Gagne V, Marois L, Levesque JM, et al. Modulation of monosodium urate crystalinduced responses in neutrophils by the myeloid inhibitory C-type lectin-like receptor: potential therapeutic implications. Arthritis Res Ther 2013;15:R73.
61. Neumann K, Castineiras-Vilarino M, Hockendorf U, et al. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity 2014;40:389-99.
62. Shio MT, Eisenbarth SC, Savaria M, et al. Malarial hemozoin activates the NLRP3 inflammasome through Lyn and Syk kinases. PLoS Pathog 2009;5(8):e1000559.
63. Aouba A, Deshayes S, Frenzel L, et al. Efficacy of anakinra for various types of crystal-induced arthritis in complex hospitalized patients: a case series and review of the literature. Mediators Inflamm 2015;2015:792173.
64. Schlesinger N, Alten RE, Bardin T, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012;71:1839-48.
65. Joosten LA, Crian TO, Azam T, et al. Alpha-1-anti-trypsin-Fc fusion protein ameliorates gouty arthritis by reducing release and extracellular processing of IL-1β and by the induction of endogenous IL-1Ra. Ann Rheum Dis 2016;75:1219-27.
66. Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381:1905-15.
67. Ridker PM, Thuren T, Zalewski A, Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 2011;162:597-605.
68. Abderrazak A, Couchie D, Mahmood DF, et al. Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2. Ki mice fed a high-fat diet. Circulation 2015;131:1061-70.
69. Coll RC, Robertson AA, Chae JJ, et al. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med 2015;21:248-55.
70. Youm YH, Nguyen KY, Grant RW, et al. The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. Nat Med 2015;21:263-9.
71. Conrad M, Angeli JP, Vandenabeele P, Stockwell BR. Regulated necrosis: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2016;15:348-66.
72. Parry TL, Melehani JH, Ranek MJ, Willis MS. Functional amyloid signaling via the inflammasome, necrosome, and signalosome: new therapeutic targets in heart failure. Front Cardiovasc Med 2015;2:25.
73. Willis MS, Patterson C. Proteotoxicity and cardiac dysfunction. Alzheimer's disease of the heart? N Engl J Med 2013;368:455-64.
74. Zimmer S, Grebe A, Bakke SS, et al. Cyclodextrin promotes atherosclerosis regression via macrophage reprogramming. Sci Transl Med 2016;8:333ra50.
75. Allen KC, Champlain AH, Cotliar JA, et al. Risk of anaphylaxis with repeated courses of rasburicase: a Research on Adverse Drug Events and Reports (RADAR) project. Drug Saf 2015;38:183-7.
76. Cheuk DK, Chiang AK, Chan GC, Ha SY. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer. Cochrane Database Syst Rev 2010;6: CD006945.
77. Demento SL, Eisenbarth SC, Foellmer HG, et al. Inflammasome-activating nanoparticles as modular systems for optimizing vaccine efficacy. Vaccine 2009;27:3013-21.